Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?
<p><strong>Background</strong> Immune checkpoint inhibitors (ICI) improve survival but cause immune-related adverse events (irAE). We sought to determine if CTCAE classification, IBD biomarkers/endoscopic/histological scores correlate with irAE colitis outcomes.</p> <p>...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| 格式: | Journal article |
| 语言: | English |
| 出版: |
Springer Nature
2020
|
| _version_ | 1826294212627267584 |
|---|---|
| author | Cheung, VTF Gupta, T Olsson-Brown, A Subramanian, S Sasson, SC Heseltine, J Fryer, E Collantes, E Sacco, JJ Pirmohamed, M Simmons, A Klenerman, P Tuthill, M Protheroe, AS Chitnis, M Fairfax, BP Payne, MJ Middleton, MR Brain, O |
| author_facet | Cheung, VTF Gupta, T Olsson-Brown, A Subramanian, S Sasson, SC Heseltine, J Fryer, E Collantes, E Sacco, JJ Pirmohamed, M Simmons, A Klenerman, P Tuthill, M Protheroe, AS Chitnis, M Fairfax, BP Payne, MJ Middleton, MR Brain, O |
| author_sort | Cheung, VTF |
| collection | OXFORD |
| description | <p><strong>Background</strong>
Immune checkpoint inhibitors (ICI) improve survival but cause immune-related adverse events (irAE). We sought to determine if CTCAE classification, IBD biomarkers/endoscopic/histological scores correlate with irAE colitis outcomes.</p>
<p><strong>Methods</strong>
A dual-centre retrospective study was performed on patients receiving ICI for melanoma, NSCLC or urothelial cancer from 2012 to 2018. Demographics, clinical data, endoscopies (reanalysed using Mayo/Ulcerative Colitis Endoscopic Index of Severity (UCEIS) scores), histology (scored with Nancy Index) and treatment outcomes were analysed.</p>
<p><strong>Results</strong>
In all, 1074 patients were analysed. Twelve percent (134) developed irAE colitis. Median patient age was 66, 59% were male. CTCAE diarrhoea grade does not correlate with steroid/ infliximab use. G3/4 colitis patients are more likely to need infliximab (p < 0.0001) but colitis grade does not correlate with steroid duration. CRP, albumin and haemoglobin do not correlate with severity. The UCEIS (p = 0.008) and Mayo (p = 0.016) scores correlate with severity/infliximab requirement. Patients with higher Nancy indices (3/4) are more likely to require infliximab (p = 0.03).</p>
<p><strong>Conclusions</strong>
CTCAE assessment does not accurately reflect colitis severity and our data do not support its use in isolation, as this may negatively impact timely management. Our data support utilising endoscopic scoring for patients with >grade 1 CTCAE disease, and demonstrate the potential prognostic utility of objective histologic scoring.</p> |
| first_indexed | 2024-03-07T03:42:09Z |
| format | Journal article |
| id | oxford-uuid:be45ece5-096f-4c97-b4bf-8d94e23ddf5b |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T03:42:09Z |
| publishDate | 2020 |
| publisher | Springer Nature |
| record_format | dspace |
| spelling | oxford-uuid:be45ece5-096f-4c97-b4bf-8d94e23ddf5b2022-03-27T05:38:06ZImmune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:be45ece5-096f-4c97-b4bf-8d94e23ddf5bEnglishSymplectic ElementsSpringer Nature2020Cheung, VTFGupta, TOlsson-Brown, ASubramanian, SSasson, SCHeseltine, JFryer, ECollantes, ESacco, JJPirmohamed, MSimmons, AKlenerman, PTuthill, MProtheroe, ASChitnis, MFairfax, BPPayne, MJMiddleton, MRBrain, O<p><strong>Background</strong> Immune checkpoint inhibitors (ICI) improve survival but cause immune-related adverse events (irAE). We sought to determine if CTCAE classification, IBD biomarkers/endoscopic/histological scores correlate with irAE colitis outcomes.</p> <p><strong>Methods</strong> A dual-centre retrospective study was performed on patients receiving ICI for melanoma, NSCLC or urothelial cancer from 2012 to 2018. Demographics, clinical data, endoscopies (reanalysed using Mayo/Ulcerative Colitis Endoscopic Index of Severity (UCEIS) scores), histology (scored with Nancy Index) and treatment outcomes were analysed.</p> <p><strong>Results</strong> In all, 1074 patients were analysed. Twelve percent (134) developed irAE colitis. Median patient age was 66, 59% were male. CTCAE diarrhoea grade does not correlate with steroid/ infliximab use. G3/4 colitis patients are more likely to need infliximab (p < 0.0001) but colitis grade does not correlate with steroid duration. CRP, albumin and haemoglobin do not correlate with severity. The UCEIS (p = 0.008) and Mayo (p = 0.016) scores correlate with severity/infliximab requirement. Patients with higher Nancy indices (3/4) are more likely to require infliximab (p = 0.03).</p> <p><strong>Conclusions</strong> CTCAE assessment does not accurately reflect colitis severity and our data do not support its use in isolation, as this may negatively impact timely management. Our data support utilising endoscopic scoring for patients with >grade 1 CTCAE disease, and demonstrate the potential prognostic utility of objective histologic scoring.</p> |
| spellingShingle | Cheung, VTF Gupta, T Olsson-Brown, A Subramanian, S Sasson, SC Heseltine, J Fryer, E Collantes, E Sacco, JJ Pirmohamed, M Simmons, A Klenerman, P Tuthill, M Protheroe, AS Chitnis, M Fairfax, BP Payne, MJ Middleton, MR Brain, O Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way? |
| title | Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way? |
| title_full | Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way? |
| title_fullStr | Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way? |
| title_full_unstemmed | Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way? |
| title_short | Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way? |
| title_sort | immune checkpoint inhibitor related colitis assessment and prognosis can ibd scoring point the way |
| work_keys_str_mv | AT cheungvtf immunecheckpointinhibitorrelatedcolitisassessmentandprognosiscanibdscoringpointtheway AT guptat immunecheckpointinhibitorrelatedcolitisassessmentandprognosiscanibdscoringpointtheway AT olssonbrowna immunecheckpointinhibitorrelatedcolitisassessmentandprognosiscanibdscoringpointtheway AT subramanians immunecheckpointinhibitorrelatedcolitisassessmentandprognosiscanibdscoringpointtheway AT sassonsc immunecheckpointinhibitorrelatedcolitisassessmentandprognosiscanibdscoringpointtheway AT heseltinej immunecheckpointinhibitorrelatedcolitisassessmentandprognosiscanibdscoringpointtheway AT fryere immunecheckpointinhibitorrelatedcolitisassessmentandprognosiscanibdscoringpointtheway AT collantese immunecheckpointinhibitorrelatedcolitisassessmentandprognosiscanibdscoringpointtheway AT saccojj immunecheckpointinhibitorrelatedcolitisassessmentandprognosiscanibdscoringpointtheway AT pirmohamedm immunecheckpointinhibitorrelatedcolitisassessmentandprognosiscanibdscoringpointtheway AT simmonsa immunecheckpointinhibitorrelatedcolitisassessmentandprognosiscanibdscoringpointtheway AT klenermanp immunecheckpointinhibitorrelatedcolitisassessmentandprognosiscanibdscoringpointtheway AT tuthillm immunecheckpointinhibitorrelatedcolitisassessmentandprognosiscanibdscoringpointtheway AT protheroeas immunecheckpointinhibitorrelatedcolitisassessmentandprognosiscanibdscoringpointtheway AT chitnism immunecheckpointinhibitorrelatedcolitisassessmentandprognosiscanibdscoringpointtheway AT fairfaxbp immunecheckpointinhibitorrelatedcolitisassessmentandprognosiscanibdscoringpointtheway AT paynemj immunecheckpointinhibitorrelatedcolitisassessmentandprognosiscanibdscoringpointtheway AT middletonmr immunecheckpointinhibitorrelatedcolitisassessmentandprognosiscanibdscoringpointtheway AT braino immunecheckpointinhibitorrelatedcolitisassessmentandprognosiscanibdscoringpointtheway |